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http://dx.doi.org/10.1016/j.ccell.2014.09.003SUMMARYHepatocellular carcinoma (HCC), the fastest rising cancer in the United States and increasing in Europe, often
occurs with nonalcoholic steatohepatitis (NASH). Mechanisms underlying NASH andNASH-induced HCC are
largely unknown. We developed a mouse model recapitulating key features of human metabolic syndrome,
NASH, and HCC by long-term feeding of a choline-deficient high-fat diet. This induced activated intrahepatic
CD8+ T cells, NKT cells, and inflammatory cytokines, similar to NASH patients. CD8+ T cells and NKT cells but
not myeloid cells promote NASH and HCC through interactions with hepatocytes. NKT cells primarily cause
steatosis via secreted LIGHT, while CD8+ and NKT cells cooperatively induce liver damage. Hepatocellular
LTbR and canonical NF-kB signaling facilitate NASH-to-HCC transition, demonstrating that distinct molecu-
lar mechanisms determine NASH and HCC development.Significance
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Hepatocellular carcinoma (HCC) is the most common primary
liver malignancy and the third most common cause of cancer-
related death worldwide, with a rising incidence in developing
and industrialized countries (Jemal et al., 2011). The most prev-
alent risk factors for HCC development are chronic hepatitis due
to hepatitis B virus or hepatitis C virus (HCV) infection or chronic
alcohol consumption (El-Serag, 2011).
A strong link between obesity and cancer is well-established,
and a body mass index (BMI) > 25 kg/m2 increases the risk for
cancer (Calle and Kaaks, 2004). A dramatic rise in cancer inci-
dence is expected due to high caloric intake, smoking and
sedentary lifestyle, doubling within the next two decades (Stew-
art and Wild, 2014). A modest rise in BMI significantly elevates
the risk for HCC and other cancers (e.g., pancreatic carcinoma
and gastrointestinal [GI] cancer) (Calle and Kaaks, 2004). In
recent years, obesity leading to metabolic syndrome, steatosis,
and steatohepatitis has attracted increased attention because
of increased HCC incidence in Western countries (White et al.,
2012). In line, HCC is the most rapidly increasing cancer type
in the United States, with 19,160 new cases and 16,780 deaths
in 2007 (American Cancer Society, 2007).
Enhanced fat uptake by hepatocytes leads to nonalcoholic
fatty liver disease (NAFLD), comprising a spectrum of liver disor-
ders ranging from fatty liver (steatosis) to nonalcoholic steatohe-
patitis (NASH), which can proceed to fibrosis, cirrhosis, and HCC
(Anstee and Day, 2013). Thus, increased fat uptake, hepatic lipid
accumulation, and NASH represent incremental risk factors for
HCC. At the same time, there is no established pharmacological
treatment for NASH, and therapy for HCC is limited (Michelotti
et al., 2013).
A ‘‘two-hit hypothesis’’ has been proposed for NASH pro-
gression from simple liver steatosis. Lipid accumulation in hepa-
tocytes is considered the first step in NASH development;
however, a second hit promoting oxidative stress, inflamma-
tion, DNA damage, hepatocyte cell death, or fibrosis is needed
(Caballero et al., 2009).
In C57BL/6mice, NASH-like liver pathology can be induced by
a methionine-choline deficient diet (MCD) or a choline-deficient
diet (CD) but not by a high-fat diet (HFD). However, C57BL/6
mice fed an MCD or a CD do not develop obesity or metabolicFigure 1. Long-Term CD-HFD Leads to Metabolic Syndrome in C57BL
(A) Weight development in male ND and CD-HFD C57BL/6 mice.
(B) Quantitative analysis of the body composition by MRI. Fat (left) and lean mas
(C) IPGTT performed with 6-month-old male ND and CD-HFD C57BL/6 mice (n =
(D) Pyruvate tolerance test performed with 10-month-old male C57BL/6 mice (N
(E) MRI analyses on livers of 6-month-old ND and CD-HFD C57BL/6 mice. T1 (f
TurboRare visualizes increase in subcutaneous and abdominal fat and hepatic li
(F) Quantitative analysis of liver composition by MRI. Fat (left) and lean mass (rig
(G) Quantification of liver triglyceride content in 3-, 6-, and 12-month-old ND and
(H) Quantification of serum cholesterol (nR 8 each).
(I) Quantification of serum ALT in male C57BL/6 mice (nR 8 each).
(J) Representative Sudan red staining illustrating fat accumulation in livers of ND
(K) Representative H&E staining of 12-month-old CD-HFD C57BL/6 mice illustratin
and satellitosis (arrow) similar to human NASH pathology (right image). The scale
(L) Electronmicroscopic images of mitochondria isolated from 6-month-old ND an
bar represents 500 nm.
All data are presented as mean ± SEM. See also Figure S1.
Csyndrome but rather develop weight loss or cachexia (Hebbard
and George, 2011). Thus, this approach does not recapitulate
NASH and its consequences in humans. Choline deficiency
is known to exacerbate NAFLD and NASH (Corbin and Zeisel,
2012; Guerrerio et al., 2012). Moreover, humans with inadequate
choline uptake have defects in hepatic lipoprotein secretion,
oxidative damage caused by mitochondrial dysfunction, and
endoplasmic reticulum (ER) stress (Corbin and Zeisel, 2012).
Choline deprivation leads to fatty liver development (Zeisel and
da Costa, 2009). At least 90% of the US population does not
meet the recommended intake for choline (Zeisel and Caudill,
2010).
The precise mechanisms leading to dietary-induced HCC are
unknown, and appropriate mouse models for studying NAFLD-
induced HCC development are lacking. Concomitant injection
of a chemical carcinogen (e.g., diethyl-nitrosamine [DEN]) and
HFD was studied in comparison with DEN-induced liver carcino-
genesis under a normal diet (ND) (Park et al., 2010). This study
revealed increased HCC, linking the inflammation-promoting
cytokines IL1b, IL6, and TNF to HFD-induced obesity. An
HFD led to enhanced tumorigenesis in a liver cancer model
(NEMODhep mice) (Wunderlich et al., 2008) and caused progres-
sion of chronic ER stress to oxidative stress, finally resulting in
HCC (Nakagawa et al., 2014).
On the basis of the clinical observations of choline deficiency
in NASH patients (Corbin and Zeisel, 2012; Guerrerio et al.,
2012), we combined choline deficiency with an HFD (CD-HFD)
to investigate hepatic steatosis, NASH, and HCC development.
RESULTS
Long-Term CD-HFD Causes Features of Metabolic
Syndrome, Liver Damage, and NASH in C57BL/6 Mice
We first studied the effects of long-term CD-HFD feeding on
body weight, glucose metabolism, and liver integrity in C57BL/
6 mice. A constant rise in body weight was observed in male
and female mice (Figure 1A; Figure S1A available online)
compared with ND mice. Long-term HFD resulted in similar
body weight gain over time (Figure S1B). Total food intake was
similar between groups (Figure S1C). Whole-body echo mag-
netic resonance imaging (MRI) revealed significantly increased
body fat mass in male and female CD-HFD mice compared/6 Mice
s (right) from 10-month-old male ND and CD-HFD C57BL/6 mice (n = 5 each).
3 each).
D, n = 9; CD-HFD, n = 10).
ast low-angle shot [FLASH]) OUT phase: dark color indicative of steatosis. T2
pid accumulation (bright regions) in CD-HFD mice.
ht) from 10- to 11-month-old ND and CD-HFD C57BL/6 mice (n = 5 each).
CD-HFD C57BL/6 mice (nR 8 each).
and CD-HFD C57BL/6 mice. The scale bar represents 100 mm.
g NASH. Accumulation of MDB (arrowhead), ballooned hepatocytes (asterisk),
bar represents 50 mm.
dCD-HFDC57BL/6mice. Arrowhead: widened and rounded cristae. The scale
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could be observed (Figure 1B; Figure S1D). Metabolic analyses
with an intraperitoneal glucose tolerance test (IPGTT) revealed
an impaired glucose response in CD-HFD and HFD mice (Fig-
ure 1C; Figures S1E and S1F). Mice on a CD-HFD produced
significantly more glucose upon pyruvate injection (Figure 1D;
Figure S1E), indicating aberrant gluconeogenesis in CD-HFD
mice.
MRI analysis revealed liver steatosis and subcutaneous and
abdominal fat accumulation in CD-HFD but not ND mice (Fig-
ure 1E). In line, quantitation of MRI analysis showed a strong
increase in fat mass, as well as an increase in lean mass in the
livers of CD-HFD mice (Figure 1F; Figure S1G). This was consis-
tent with strongly increased triglyceride deposition in the livers
of CD-HFD mice (Figure 1G). Serum analyses revealed rising
cholesterol levels, especially of low-density lipoprotein, but unal-
tered triglyceride levels (Figure 1H; Figure S1H; data not shown).
CD-HFD and HFD mice displayed increased cholesterol levels
(Figure S1I). In line, liver cholesterol levels were significantly
elevated upon CD-HFD (Figure S1J). Liver steatosis was accom-
panied by progressive liver damage, reflected by increased
serum alanine transaminase (ALT) and aspartate transaminase
(AST) levels (Figure 1I; Figures S1K and S1L). In contrast, HFD
mice lacked liver damage at 6 months (data not shown). No sig-
nificant alterations in serum bilirubin or alkaline phosphatase
levels were found, indicating that long-term CD-HFD does not
cause significant biliary damage. However, a modest increase
in bile acid levels was measured in serum (Figure S1M). Hema-
toxylin and eosin (H&E) and Sudan red staining of liver sections
further illustrated the progression from mild to severe steatosis
over time. Quantification of the Sudan red+ area and the sizes
of lipid droplets revealed a strong increase of large fatty droplets
culminating in macrovesicular steatosis (Figure 1J; Figures S1N
and S1O).
In addition to severe steatosis, the livers of CD-HFD mice dis-
played ballooned hepatocytes, immune cell infiltration, satellito-
sis, Mallory-Denk body (MDB) formation, and glycogeneated
nuclei, all features reminiscent of human NASH (Figure 1K).
Furthermore, signs of oxidative stress were observed in the livers
of CD-HFD mice (Figure S1P). Screening analyses of mRNA
revealed significant downregulation of several genes involved
in lipid metabolism in CD-HFD compared with ND mice (Fig-
ure S1Q). Genes such as hepatic lipase or lipoprotein lipase,
regulated by inflammatory cells and their secreted factors (e.g.,
cytokines, chemokines; Lo et al., 2007) and genes involved in
cholesterol biosynthesis were significantly deregulated.
Mitochondrial alterations found in the hepatocytes of NASH
patients (Pirola et al., 2013), such asmitochondrial structural def-Figure 2. CD-HFD Induces Enhanced Presence and Activation of Hepa
(A) Representative histology and IHC on liver sections of 6-month-old ND (upper ro
F4/80, MHCII, and Ly6G. The scale bar represents 50 mm.
(B–I) Representative zebra plots and quantification of flow cytometric analyses co
cells (B), CD4+ and CD8+ T cells (C), CD44+CD8+CD62L T cells (D), CD69+CD8+
staining of CD3+NK1.1+ NKT cells to quantify numbers of type I and type II NKT
monocytes (I) are shown.
(J) Masson’s trichrome staining (MAS) and aSMA IHC on liver sections of 12-mo
(K) Immunofluorescence staining on primary HSC co-cultured with ND and CD-H
droplets are quantified.
All data are presented as mean ± SEM. See also Figure S2.
Cicits, were also observed in CD-HFD mice. Mitochondrial cristae
were shortened, more rounded, and partially enlarged in size,
with a balloon-like appearance (Figure 1L). Moreover, mitochon-
dria displayed reduced ATP production and increased vulnera-
bility to extracellular calcium (Figures S1R and S1S).
Infiltration and Activation of Immune Cells in Livers of
CD-HFD C57BL/6 Mice
We next investigated whether CD-HFD feeding affects the ho-
meostasis of hepatic immune cells, similar to what has been
postulated for NASH patients (Caballero et al., 2012; De Vito
et al., 2012). Intrahepatic immune cells comprised CD3+
T cells, F4/80+ macrophages, MHCII+ cells, and Ly6G+ neutro-
phils in CD-HFD but not in ND or HFD mice (Figure 2A; Fig-
ure S2A). Whereas numbers of CD3CD19+ B cells remained
unchanged (Figure 2B), strong increases in CD4+ and CD8+
T cells were observed in CD-HFD compared with ND mice (Fig-
ure 2C). Furthermore, CD8+ and CD4+ T cells expressed more
CD44 and CD69, indicating local T cell activation (Figures 2D
and 2E; Figures S2B and S2C). Enhanced secretion of TNF by
CD8+ T cells and IL-17 by CD4+ T cells was observed (Figures
S2D and S2E). Moreover, significant increases in hepatic NKT
cells (CD3+NK1.1+), especially in a-GalCer-CD1d negative
type II NKT cells, and regulatory T cells were found in CD-HFD
mice (Figures 2F–2H). Elevated T cells were accompanied by
increased proinflammatory Ly6Chi monocytes, Ly6G+ granulo-
cytes, and F4/80+ Kupffer cells (Figure 2I; Figures S2F and
S2G). Splenic immune cells displayed a similar phenotype, sug-
gesting systemic activation of immune cells upon CD-HFD (Fig-
ure S2H). In addition, TNF superfamily (TNFSF) cytokines and
Tgfb, Ifng, and Il1b were upregulated in hepatic lymphocytes
from CD-HFD mice (Figure S2I). In particular, LTbR ligands
(Light, Lta, and Ltb) were strongly upregulated.
Long-termCD-HFDcausedmildpericellular fibrosis accompa-
nied by elevated aSMA+ cells indicative of hepatic stellate cell
(HSC) activation (Figure 2J). In line, expression of genes indica-
tive of fibrosis or liver tissue remodeling was enhanced (Fig-
ure S2J). Splenocytes from CD-HFD mice sufficed to activate
isolated HSCs in vitro, reflected by an increase in aSMA+ expres-
sion anda lossof vitaminAdroplets,whereasNDsplenocytesdid
not (Figure 2K). These data suggest a contribution of activated
immune cells to liver tissue remodeling in the CD-HFD model.
Long-Term CD-HFD Causes HCC in C57BL/6 Mice
Mice were sacrificed at 12 months, and livers were analyzed
macro- and microscopically. HFD and CD-HFD mice showed
enlarged, pale yellow livers indicative of steatosis. One of 40
HFD mice (incidence 2.5%) displayed a tumor. In contrast,tic Lymphocytes and Mild Fibrosis
w) and CD-HFD (lower row) C57BL/6 mice. From left to right: H&E, B220, CD3,
mparing 6-month-old ND and CD-HFD C57BL/6 mice (nR 4). CD19+CD3 B
CD62L T cells (E), CD19CD3+NK1.1+ NKT cells (F), a-Gal Cer CD1-tetramer
cells (G), Foxp3+CD4+ regulatory T cells (H), and CD11b+Ly6C+ inflammatory
nth-old ND and CD-HFD C57BL/6 mice. The scale bar represents 50 mm.
FD splenocytes. The scale bar represents 25 mm. aSMA+ cells and vitamin A+
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Figure 3. Long-Term CD-HFD Leads to HCC
Development in C57BL/6 Mice
(A) Macroscopy of livers from 12-month-old ND,
HFD, or CD-HFD C57BL/6 mice, with arrowhead
pointing toward HCC. The scale bar represents
5 mm.
(B) Graph summarizing C57BL/6 mice without
tumor (NT) and with tumor (T) on ND, HFD, and
CD-HFD. Symbols depict individual mice.
(C) Histology and IHC of livers derived from 12-
month-old C57BL/6 mice on ND (upper row) and
CD-HFD with HCC (lower row). Dashed lines
depict HCC border. The scale bars represent H&E:
2 mm (low) and 200 mm (high); collagen IV: 200 mm;
Ki67: 100 mm (depicted by arrowheads).
(D) Immunoblot analyses of liver homogenates
from ND and CD-HFD C57BL/6 mice with or
without HCC (NT).
(E) H&E stains of HCC of various growth patterns.
The scale bar represents 50 mm.
(F) Distribution of the growth patterns per HCC
analyzed. Each column represents one individual
mouse.
(G) Karyoplot of an aCGH analysis on nine HCCs
from CD-HFD C57BL/6 mice and two samples of
livers without HCC (NT). The q-arm of each chro-
mosome is shown, and dark horizontal bars within
the symbolized chromosomes represent G bands.
See also Figure S3 and Table S1.
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male and female mice being affected at similar rates (incidence
25%) (Figures 3A and 3B; Figures S3A and S3B). ND livers
lacked tumors.
Tumors were further analyzed by immunohistochemistry
(IHC). Loss of collagen IV networks, broadening of liver cell554 Cancer Cell 26, 549–564, October 13, 2014 ª2014 Elsevier Inc.cords, and Ki67+ proliferating tumor cells
were observed within the tumor lesions,
thus tumors resembled human HCC
(Figure 3C; Figure S3C). In addition,
HCCs from CD-HFD and HFD mice were
positive for the tumor markers GP73,
a-fetoprotein, and the oval cell marker
A6 but negative for glutamine synthetase
(Figure S3D).
Immunoblot analysis of HCC confirmed
enhanced expression of GP73, the antia-
poptotic protein BCL2, and the prolif-
eration marker proliferating cell nuclear
antigen when compared with ND or CD-
HFD livers without tumors (NT). Several
signaling pathways (including NF-kB,
AKT, cJUN, mTOR, and p38) are asso-
ciated with liver cancer (Moeini et al.,
2012). Indeed, phosphorylation of AKT,
cJUN, and p53 was found within HCC
(Figure 3D). CD-HFD induced phosphory-
lation of p65, p38, mTOR, and NUR77 not
only within HCC nodules but also in NT
tissue. In contrast, HFD did not activate
p38, mTOR, or NUR77 (Figure S3E).Accordingly, IHC revealed enhanced nuclear p65 translocation
in immune cells and hepatocytes of CD-HFD livers but not in
ND or HFD livers (Figure S3F). Moreover, CD-HFD andHFD livers
displayed an increase in Ki67+ hepatocytes compared with ND,
indicative of compensatory proliferation (Figure S3F). In addition,
sequencing of Tp53 exons revealed missense mutations in 4 of
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(Figure S3G).
CD-HFD-Induced HCCs Are Heterogeneous in Growth,
Genomic Alterations, and Gene Expression Patterns
Histological analysis of CD-HFD-induced HCC revealed different
growth patterns, with predominantly fatty change and solid
growth, sometimes with cytoplasmic inclusions or (thick) trabec-
ular growth, and poor differentiation in one case (Figures 3E
and 3F; Figure S3H). Thus, CD-HFD-induced HCC are heteroge-
neous. For molecular characterization, HCC were microdis-
sectedandanalyzedbyarray comparative genomic hybridization
analysis (aCGH), revealing chromosomal aberrations in all HCCs
but not in control tissue. NT livers did not display chromosomal
aberrations. Hence, CD-HFD does not directly induce chromo-
somal alterations in the liver (Figure 3G). Although amplifications
on chromosomes 1, 15, 16, and 18 were found in 4 of the 9 HCCs
(Figure S3I), no clear recurrent pattern was found (p = 0.35). Syn-
teny analyses revealed thatmost of the genes found to be altered
in copy number in CD-HFD livers were congruent with loci found
to be changed in human cryptogenicHCC (Schlaeger et al., 2008)
(Figure S3J and Table S1). Moreover, clonality of individual HCC
nodules spreading within one liver was found (Figure S3K).
Application of an expression signature to distinguish prolifera-
tive and aggressive from differentiated and less aggressive
hepatoblastoma or HCC (Cairo et al., 2008) confirmed that CD-
HFD-induced HCC are heterogeneous, ranging from HCC with
increased expression of differentiation genes to HCC with high
expression of proliferation genes (Figure S3L). Moreover, we as-
sessed the expression pattern of selected oncogenes and tumor
suppressors deregulated in HCC (Zender et al., 2010). Of 78
genes tested, we identified significant deregulation of several
genes involved in the regulation of transcription, cell cycle, and
proliferation and apoptosis (Figures S3M and N), including the
tumor suppressor genes Tp53, Apc, and Axin1.
Lymphocytes, LTbR, and NF-kB Signaling in
Hepatocytes Facilitate CD-HFD-Induced Liver Cancer
Both protective and procarcinogenic roles have been attributed
to immune cells in liver cancer, depending on the type of model
and the study performed (Vucur et al., 2010). Therefore, Rag1/
mice, lacking mature B, T, and NKT cells and unable to mount
adaptive immune responses and Ccr2/ mice, which have
reduced numbers of proinflammatory monocytes and myeloid-
derived suppressor cells, were fed with CD-HFD and analyzed
for liver carcinogenesis.
Because CD-HFD led to p65 activation and expression of
LTbR ligands in the livers of C57BL/6 mice, we analyzed
mice with hepatocyte-specific deficiencies in canonical NF-kB
(IkkbDhep mice) and LTbR signaling (LtbrDhep mice) (Figure S4A).
Importantly, CD-HFD Rag1/ mice lacked HCC, whereas
Ccr2/ mice displayed a similar HCC incidence as C57BL/6
mice. Moreover, CD-HFD LtbrDhep and IkkbDhep mice displayed
a significant reduction or trend toward reduction in HCC inci-
dence (Figures 4A and 4B). IHC further confirmed HCCs in
Ccr2/, LtbrDhep, and IkkbDhep mice, which were similar to
HCCs in CD-HFD C57BL/6 mice, as well as the absence of liver
tumorigenesis in Rag1/ mice (Figures 4C; Figure S4B). Real-
time PCR for HCC-associated genes, aCGH, and histologicalCanalyses showed that HCC from CD-HFD Ccr2/, LtbrDhep,
and IkkbDhep mice were qualitatively similar to those from CD-
HFD C57BL/6 mice (Figures S4C–S4F).
Analysis and quantification of hepatic lipid accumulation illus-
trated severe steatosis inCcr2/ and IkkbDhep mice, a reduction
in LtbrDhep mice, as well as an absence in CD-HFD Rag1/mice
(Figures 4D and 4E). Notably, triglyceride levels were unchanged
in CD-HFD Rag1/ and LtbrDhep livers compared with ND
C57BL/6 livers. In contrast, triglyceride accumulation in CD-
HFD Ccr2/ and IkkbDhep livers was similar to CD-HFD
C57BL/6 livers (Figure 4F). CD-HFD Ccr2/, IkkbDhep, and
LtbrDhep mice displayed elevated serum cholesterol and ALT
levels similar to CD-HFD C57BL/6 mice (Figure S4G). In line,
CD-HFD LtbrDhep mice showed similar body weights to CD-
HFD C57BL/6 mice (Figure S4H).
Moreover, histological features of NASH, such as severe
steatosis, ballooning hepatocytes, satellitosis, and MDB, were
absent in Rag1/ livers but present in LtbrDhep, Ccr2/, and
IkkbDhep livers (Figure S4I). Fibrosis was observed in LtbrDhep,
Ccr2/, and IkkbDhep livers but not Rag1/ livers (Figure S4I).
IHC and flow cytometric analyses of LtbrDhep mice revealed the
presence of activated CD8+ and NKT cells (Figures S4J and
S4K). Also, the deregulation of lipid metabolism genes in CD-
HFD C57BL/6 livers described above was partially prevented
in CD-HFD LtbrDhep livers (Figure S4L). Despite the presence
of activated immune cells, NASH, and overt liver damage in
CD-HFD LtbrDhep mice, they showed a strongly reduced HCC
incidence, suggesting a direct influence of LTbRsignaling on liver
carcinogenesis.
Our data demonstrate that lymphocytes directly contribute to
liver steatosis, NASH, and carcinogenesis in the CD-HFD model
and that LTbR and canonical NF-kB signaling in hepatocytes
interfere with the transition from NASH to HCC.
Role of Lymphocytes in Liver Damage and Steatosis
Consistentwithhistologicaldata,MRIanalysesconfirmed the lack
of steatosis in CD-HFDRag1/ liverswithout significant changes
in liver lean mass compared with C57BL/6. However, subcutane-
ous and abdominal fat was present (Figures 5A and 5B).
Serumanalysis showed no increase in cholesterol, ALT, or AST
levels in CD-HFD Rag1/ mice compared with ND C57BL/6
mice (Figures 5C; Figure S5A). ALT, AST, cholesterol, and liver
triglycerides were not significantly changed in ND Rag1/
mice compared with ND C57BL/6 mice (data not shown).
Alterations in lipid metabolism or uptake might be a reason for
the absence of fat accumulation in livers and reduced serum
cholesterol in CD-HFD Rag1/ mice. Immunoblot analysis re-
vealed that CD-HFD Rag1/ mice lacked phosphorylation of
p65, mTOR, and NUR77 (Figure 5D). Moreover, transcriptional
analyses demonstrated that the deregulation of several genes
involved in lipid metabolism observed in CD-HFD C57BL/6 mice
was partially prevented in CD-HFD Rag1/mice (Figure 5E).
To investigate whether Rag1/ mice display a reduced ca-
pacity to take up fatty acids (FAs) from the circulation or the GI
tract, we intravenously or orally administered traceable FAs to
ND C57BL/6 and Rag1/ mice. No difference in FA uptake
into C57BL/6 and Rag1/ livers was observed with either
administration route (Figures S5B and S5C). Hepatocytes iso-
lated from C57BL/6 or Rag1/ mice also showed no differenceancer Cell 26, 549–564, October 13, 2014 ª2014 Elsevier Inc. 555
Figure 4. HCC Depends on the Presence of
Lymphocytes, LTbR, and Canonical NF-kB
Signaling
(A) Macroscopy of livers from 12-month-old CD-
HFDRag1/,Ccr2/, LtbrDhep, and IkkbDhep mice
with (arrowheads) or without HCC. The scale bar
represents 5 mm.
(B) Graph representing numbers of mice without
tumor (NT) andwith tumor (T). Each symbol depicts
one individual mouse; statistical significance
compared with CD-HFD C57BL/6 mice is shown.
(C) Histological analysis of livers derived from 12-
month-old CD-HFD Rag1/, Ccr2/, LtbrDhep,
and IkkbDhepmice (from left to right). H&E stains are
shown, with dashed line depicting HCC borders,
collagen IV staining (both scale bars represent
200 mm), and Ki67 staining (the scale bar repre-
sents 100 mm).
(D) H&E and Sudan red staining for fat accumula-
tion in livers of 12-month-old CD-HFD Rag1/,
Ccr2/, LtbrDhep, and IkkbDhep mice (from left to
right; the scale bar represents 100 mm).
(E) Quantification of total Sudan red+ area (n R 6
per genotype).
(F) Quantification of liver triglycerides (n R 12
each).
All data are presented as mean ± SEM. See also
Figure S4.
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CD8+ and NKT Cells Promote NASH and NASH-Induced HCCin their capacity to take up FA in vitro (Figure S5D). In line, CD-
HFD Rag1/ mice showed an increase in body weight similar
to C57BL/6 (Figure S5E). However, analysis of liver-to-body
weight ratios confirmed the absence of liver fat accumulation
(Figure S5F) despite body weight gain in Rag1/ mice. In addi-
tion, IPGTT revealed that CD-HFD Rag1/ mice showed
impaired glucose tolerance, similar to C57BL/6 mice (Fig-556 Cancer Cell 26, 549–564, October 13, 2014 ª2014 Elsevier Inc.ure S5G). These data demonstrate that
the phenotype of Rag1/ mice is due
not to an altered FA uptake but rather to
the lack of lymphocytes.
We next addressedwhether differences
in CD-HFD Rag1/ and C57BL/6 mice
could be due to changes in the barrier
function of the GI tract or the intestinal
microbiota diversity. Oral administration
of FITC-dextran revealed no differences
in GI barrier function. Additionally, IHC for
E-cadherin suggested intact GI barrier
structures in both genotypes (Figures
S5H and S5I). Co-housing of CD-HFD
C57BL/6 and Rag1/ mice did not alter
the CD-HFD-related phenotypes in either
genotype. In particular, no elevation of
serum cholesterol, ALT, AST, or liver tri-
glyceride levels was observed in CD-HFD
Rag1/ mice co-housed with C57BL/6
(Figure S5J). Moreover, high-throughput
sequencing of partial 16S rRNA genes
(V4 region) amplified from fecal DNA
collected from the co-housed CD-HFDC57BL/6 andRag1/mice showednodifference in phylogenetic
makeup between these genotypes (Figure S5K). In addition, anal-
ysis of the amount of endotoxin in the portal vein did not reveal
differences between CD-HFD C57BL/6 and Rag1/ mice (Fig-
ure S5L). Thesedata indicate that a leakygut barrier or differences
in microbiota are unlikely to cause the phenotypes observed in
CD-HFD Rag1/ and C57BL/6 mice.
Figure 5. Interaction with Activated Immune
Cells Triggers Hepatic Lipid Uptake
(A) MRI analyses on livers of 6-month-old ND and
CD-HFDC57BL/6 andRag1/mice. T1-weighted
FLASH OUT phase indicated lack of steatosis in
CD-HFD Rag1/ mice.
(B) Quantitative analysis of liver composition by
MRI. Lean (left) and fat mass (right) from 10-month-
old ND and CD-HFD C57BL/6 and Rag1/ mice
(n = 5 each).
(C) Quantification of serum cholesterol (left) and
ALT (right) (nR 8 each).
(D) Immunoblot analysis of 12-month-old ND and
CD-HFD C57BL/6 and Rag1/ mice.
(E) Real-time PCR analysis for lipid metabolism
genes on mRNA isolated from ND and CD-HFD
C57BL/6 and Rag1/ livers.
(F) Thin-layer chromatography to visualize FA up-
take by hepatocytes (H) upon co-cultivation with
splenocytes (S) from 6-month-old ND (left) or CD-
HFD C57BL/6 mice (right) and quantification of
the neutrallipid:phospholipid ratio.
(G) Staining with LD540 (orange) and DAPI (blue) to
visualize lipid droplet accumulation (arrowhead) in
hepatocytes co-cultured with CD-HFD spleno-
cytes and addition of FAs. The scale bar repre-
sents 20 mm. Quantification of the LD540+ area.
(H) Staining with and quantification of LD540 to
visualize lipid droplet accumulation in hepatocytes
cultured with conditioned medium from CD-HFD
splenocytes or recombinant LIGHT. The scale bar
represents 20 mm.
All data are presented as mean ± SEM. See also
Figure S5.
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CD8+ and NKT Cells Promote NASH and NASH-Induced HCCWe next investigated whether lymphocytes could trigger
enhanced FA uptake into hepatocytes by co-culturing with
splenocytes from ND C57BL/6 mice. However, no differ-
ences in FA uptake into hepatocytes with or without spleno-
cytes were observed (Figure 5F). Notably, co-culture with
activated splenocytes (from CD-HFD mice) led to signifi-
cantly enhanced FA uptake by hepatocytes, independent
of the concentration of FAs or the hepatocyte/spleno-
cyte ratio (Figure 5F; Figures S5M and S5N). Quantification
of LD540 staining revealed that co-culturing of hepato-
cytes with splenocytes from CD-HFD C57BL/6 mice led toCancer Cell 26, 549–564increased lipid accumulation and mac-
rovesicular steatosis (Figure 5G).
Next,we investigatedwhetherdirectcell
contact with splenocytes or whether im-
mune-cell-derived soluble factorsmediate
hepatic lipid uptake. Thus, primary hepa-
tocytes were cultured with CD-HFD sple-
nocyteconditioned in the absenceorpres-
ence of FA. Conditioned medium sufficed
to mediate lipid uptake into hepatocytes
(Figure 5H). Our analyses from isolated
splenocytes, intrahepatic lymphocytes,
and protein analyses of their supernatant
indicated that members of the TNFSF
(e.g.,LightandLtab)werestronglyupregu-lated (Figure S2; data not shown). Therefore, we added recombi-
nant LIGHT toprimary hepatocytes. Indeed, the addition of LIGHT
sufficed to induce hepatic lipid uptake (Figure 5H).
CD8+ T Cells and NKT Cells Control NASH and NASH-
Induced HCC
Increased numbers and enhanced activation of CD8+ and NKT
cells were observed in CD-HFD C57BL/6 livers. Thus, b2m/
mice, which display strongly reduced CD8+ and NKT cells,
were fedwithCD-HFDandanalyzed at 6 and12months. Flowcy-
tometric analysis verified significant reductions in CD8+ T cells, October 13, 2014 ª2014 Elsevier Inc. 557
Figure 6. CD8+ T Cells and NKT Cells Control Liver Damage, NASH, and HCC in a Nonredundant Manner
(A) Quantification of serum ALT and cholesterol in 6-month-old CD-HFD C57BL/6 and b2m/ mice (nR 8 each) and liver triglycerides in 12-month-old mice
(nR 11 each).
(B) Sudan red staining of liver sections (12-month-old, indicated genotypes).
(C) Representative histology and IHC on liver sections of 12-month-old CD-HFD C57BL/6 and b2m/ mice. From left to right: H&E, B220, CD3, F4/80, MHCII,
and Ly6G. The scale bar represents 50 mm.
(D) Macroscopy of livers derived from 12-month-old CD-HFD C57BL/6 and b2m/ mice. The scale bar represents 5 mm; arrowhead depicts HCC.
(E) Graph summarizing CD-HFD C57BL/6 and b2m/ mice without tumor (NT) and with tumor (T). Symbols depict individual mice.
(legend continued on next page)
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CD8+ and NKT Cells Promote NASH and NASH-Induced HCCand a-Gal Cer+ NKT cells in CD-HFD b2m/ livers compared
with CD-HFD C57BL/6 livers (Figure S6A). Aged CD-HFD
b2m/ mice showed a similar increase in body weight as CD-
HFD C57BL/6 and a trend toward reduction in liver-to-body
weight ratio (Figure S6B). Importantly, b2m/ mice were pro-
tected from CD-HFD-induced liver damage similar to Rag1/
mice (Figure 6A). In line,b2m/micedisplayedsignificant reduc-
tions in serum cholesterol and liver triglyceride levels compared
with CD-HFD C57BL/6 mice (Figure 6A). This was confirmed by
Sudan red staining (Figure 6B). All CD-HFD b2m/mice lacked
overt NASH and fibrosis (Figure S6C). In 2 of 23 mice, we
observed moderate steatosis, hepatocyte ballooning, and occa-
sional hepatic inflammatory cells (Figure 6C), histological
changes that could be considered borderline NASH.
Strikingly, CD-HFD b2 m/mice lacked HCC (Figures 6D and
6E). Immunoblot analysis revealed that b2m/ livers lacked or
had strongly reduced p65 and NUR77 phosphorylation. Phos-
phorylation of mTOR was observed in some b2m/ mice
upon CD-HFD feeding (Figure S6D). Moreover, deregulation of
genes involved in lipid metabolism in CD-HFD C57BL/6 livers
was partially prevented in b2m/ mice (Figures S6E and S6F).
We next investigated whether CD8+ and NKT cells exert
non-redundant functions in CD-HFD-induced liver disease. To
assess the role of CD8+ T cells, antibody-mediated cell depletion
was performed in CD-HFD C57BL/6 mice with established pa-
thology. Efficacy of CD8+ T cell depletion was confirmed by
flow cytometry (Figure S6G). After 4 and 8 weeks of anti-CD8
treatment and continuous CD-HFD feeding, liver damage was
rescued (Figure 6F). Notably, serum cholesterol values remained
unchanged, suggesting that CD8+ T cells trigger CD-HFD-
induced liver damage but do not affect lipid metabolism.
Because CD8+ T cells did not appear to strongly influence lipid
metabolism, we addressed whether NKT cells could influence
hepatic lipid metabolism. Sorted CD19+ B, CD4+/CD8+ T, or
NKT cells from CD-HFD C57BL/6 spleens were co-cultured
with hepatocytes, and their capacity to mediate FA uptake was
assessed (Figures 6G; Figure S6H). Only NKT cells appeared
to efficiently enhance FA uptake by hepatocytes, which was as
effective as incubation of hepatocytes with total splenocytes.
Having observed that CD-HFD splenocytes activate HSC
in vitro, we next investigatedwhether CD8+ or NKT cells can acti-
vate HSCs in the CD-HFD model. Notably, HSC activation was
strongly induced by CD-HFDNKT cells but only to aminor extent
by CD8+ T cells (Figure S6I).
These data highlight the importance of CD8+ and NKT cells in
HCC development. Moreover, CD8+ T cells do not mediate FA
uptake or HSC activation as efficiently as NKT cells but rather
contribute to CD-HFD-induced liver damage.
NKT Cell-Derived LIGHT Exacerbates Liver Damage,
NASH, and HCC Development
The LTbR ligand LIGHT (TNFSF14), one the most strongly upre-
gulated cytokines in lymphocytes from CD-HFD C57BL/6 mice,(F) Quantification of serum ALT and cholesterol in CD-HFD C57BL/6 mice. Six-m
every 4 weeks (n = 5).
(G) Thin-layer chromatography visualizing FA uptake of hepatocytes co-cultured
HFD C57BL/6 mice. Data from 3 individual mice are shown.
All data are presented as mean ± SEM. See also Figure S6.
Chas been reported to be involved in the regulation of lipid homeo-
stasis (Lo et al., 2007) and to control FA uptake of hepatocytes
in vitro. Therefore, we asked whether LIGHT deficiency would
interfere with steatosis and NASH development and reduce
HCC incidence upon CD-HFD feeding. To this end, aged CD-
HFD Light/ mice were analyzed for HCC. Macroscopic and
histological analyses of livers showed that CD-HFD Light/
mice lacked HCC (Figure 7A; Figure S7A). Serum analysis re-
vealed lower ALT and cholesterol levels in CD-HFD Light/
mice compared with C57BL/6 (Figure 7B). Sudan red staining
and quantification, as well as liver triglyceridemeasurements, re-
vealed reduced steatosis in Light/ livers (Figure 7C). Immuno-
blot analysis revealed absent or strongly reduced p65 and
NUR77 phosphorylation in CD-HFD Light/ livers; however,
absence of LIGHT did not attenuate phosphorylation of mTOR
upon CD-HFD feeding (Figure S7B). Moreover, analysis of lipid
metabolism genes in CD-HFD Light/ livers indicated that
deregulation found in CD-HFD C57BL/6 mice was almost
completely restored, resulting in expression levels similar to
ND and HFD C57BL/6 mice (Figures S7C and D). IHC revealed
a lack of NASH despite infiltrating immune cells in livers of CD-
HFD Light/mice similar to CD-HFD C57BL/6 mice (Figure 7D;
Figure S7E). Further analyses of intrahepatic T cell populations
by flow cytometry showed no difference in the number or activa-
tion status of CD8+ T cells between CD-HFD C57BL/6 and
Light/ mice. Similar to ND C57BL/6 mice, CD-HFD Light/
mice lacked any increase in intrahepatic NKT cells (Figure 7E).
Thus, LIGHT expression and the presence of NKT cells play an
important role in CD-HFD-induced steatosis, NASH, and HCC
development.
To investigate whether lack of LIGHT signaling in CD8+ T cells
could account for the observed reduction in liver damage in
Light/ mice, we blocked LTbR signaling in CD-HFD C57BL/6
mice using LTbR-Ig. Systemic administration of LTbR-Ig did
not alter CD-HFD-induced liver damage, suggesting that the
reduced liver damage seen in Light/ mice was due not to the
lack of LIGHT expression on activated CD8+ T cell but rather
primarily to the reduction of hepatic NKT cells (Figure S7F).
These data, together with the CD8+ T cell depletion experiments,
suggest that CD8+ and NKT cells cooperate to promote liver
damage.
To confirm that NKT cell-derived LIGHT is essential for
hepatocyte lipid uptake, we blocked LTbR signaling in vitro in a
hepatocyte-splenocyte co-culture. LTbR-Ig reduced the spleno-
cyte-mediated ability to enhance FA uptake (Figure S7G). Thus,
in line with data from LtbrDhep mice, hepatic LTbR signaling (i.e.,
through NKT cell-derived LIGHT) enhanced lipid uptake.
Increase of LIGHT-Expressing CD8+ T Cells
and NKT Cells in Livers of Patients with NASH
and NASH-Related HCC
We next asked whether the T cell populations and cytokines
identified in CD-HFDmice are also found in human liver diseasesonth-old mice were injected with anti-CD8 antibody and serum was analyzed
with NKT, B, CD4+, or CD8+ T cells isolated from spleens of 6-month-old CD-
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Figure 7. Lack of LIGHT Expression Protects from Liver Damage, NASH, and HCC
(A) Macroscopy of livers of 12-month-old CD-HFD C57BL/6 and Light/ mice (the scale bar represents 5 mm) and H&E and collagen IV stains (the scale bar
represents 100 mm).
(B) Quantification of serum ALT and cholesterol in 12-month-old mice (n = 10).
(C) Sudan red staining and quantification on liver sections of 12-month-old CD-HFD C57BL/6 and Light/mice; quantification of liver triglyceride levels (n = 10).
(D) Histology and IHC on liver sections of 12-month-old CD-HFD C57BL/6 and Light/ mice. From left to right: H&E, B220, CD3, F4/80, MHCII, and Ki67. The
scale bar represents 50 mm.
(E) Quantification of flow cytometry analyses for NKT cells and activation of CD8+ T cells on hepatic lymphocytes from 6-month-old ND andCD-HFDC57BL/6 and
Light/ mice (n = 3).
All data are presented as mean ± SEM. See also Figure S7.
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CD8+ and NKT Cells Promote NASH and NASH-Induced HCCinvolving steatosis (i.e., NASH, alcoholic steatohepatitis [ASH],
and chronic HCV [genotype 3] infection). Moreover, we analyzed
NASH- and HCV-related HCC (Table S2). Livers of NASH pa-
tients revealed significantly increased numbers of CD8+ T cells
compared with non-diseased livers (Figures 8A and 8B), as did
the livers of patients with ASH, chronic HCV infection, and
NASH-induced HCC (Figure S8A). A significantly increased num-
ber of CD57+CD3+ NKT cells was found in the livers of patients560 Cancer Cell 26, 549–564, October 13, 2014 ª2014 Elsevier Inc.with NASH and chronic HCV infection (Figures 8A and 8B) but
not in ASH or HCC (Figure S8A). Samples of ASH and HCC
patients lacked increased numbers of LTb+ cells, whereas
NASH displayed only a trend and HCV samples a significantly
increased number (Figures 8A and 8B; Figure S8A). Of note,
LIGHT mRNA expression was significantly enhanced in NASH
livers, but not in ASH, chronic HCV infection, or HCC (Figure 8B;
Figure S8A). Furthermore, co-immuno reactivity was found for
Figure 8. Increased LIGHT+ NKT Cells in
Livers of NASH Patients
(A) Representative IHC of human non-diseased
control livers (n = 13) and livers of NASH patients
(n = 18) for CD8+ T cells, CD3+CD57+ NKT cells,
LTb, and LIGHT expression with arrowheads indi-
cating positive cells (the scale bar represents
50 mm).
(B) Quantification of stained cells per area and
LIGHT mRNA expression.
(C) In a state of hypernutrition and concomitant
choline deficiency, activated intrahepatic NKT cells
enhance hepatocyte lipid uptake via secreted
LIGHT leading to steatosis. CD8+ T cells, NKT cells,
and associated inflammatory cytokines coopera-
tively cause liver damage and contribute to hepa-
tocellular canonical and noncanonical NF-kB
signaling facilitating NASH-to-HCC transition. Yel-
low symbols: lipid droplets.
All data are presented as mean ± SEM. See also
Figure S8 and Table S2.
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CD8+ and NKT Cells Promote NASH and NASH-Induced HCCLIGHT and CD57 or CD8, suggesting that CD8+ T cells and
CD57+CD3+ NKT cells are the major source of LIGHT (Fig-
ure S8B). Thus, as seen in CD-HFD mice, CD8+ T cells and
NKT cells are found in steatosis-related human liver diseases.
Notably, significantly enhanced LIGHT expression was only
found in the liver tissue of NASH patients and only to a minor
degree in ASH and HCV infection.
DISCUSSION
The exact contribution of immune cells to steatosis, NASH, and
HCC development is unclear. Moreover, the underlying signaling
pathways activated in parenchymal and non-parenchymal liver
cells promoting NASH and facilitating the transition from NASH
to HCC remain poorly understood.
Recently, it was reported that immune cells (e.g., NKT cells)
suppress NAFLD in short-term experiments with HFD or high-
sugar diet (Martin-Murphy et al., 2014) and prevent obesity and
metabolic disorder (Lynch et al., 2012). In contrast, immune cells
were also reported to promote obesity, tissue inflammation (Sa-Cancer Cell 26, 549–564toh et al., 2012) or NAFLD upon short-term
HFD or high-fructose diet (Bhattacharjee
et al., 2014). This discrepancy in results
might be due to an influence of the mouse
genetic background, as, for example,
Balb/c mice are resistant to diet-induced
obesity, the specific composition of diets
leading to differences in the activation
of immune cells, and the presence or
absence of hepatocyte damage, creating
an environment that attracts NKT cells.
Long-term CD-HFD, in contrast to HFD,
induced oxidative stress and mitochon-
drial damage as well as activation of
various signaling pathways and chronic
liver damage, preconditioning the liver
microenvironment. Moreover, short-termcholine-deficient amino acid-defined diet (CDAA) causes activa-
tion of inflammatory monocytes and Kupffer cell depletion
ameliorated steatohepatitis (Miura et al., 2012). In addition, a
combination of CDAA and HFD caused severe fibrosis in
NASH (Matsumoto et al., 2013).
Few of these regimens cause features of a chronic metabolic
syndrome concomitant with NASH. By applying long-term
CD-HFD, we recapitulate the process of a chronic metabolic dis-
order and NASH (Figure 8C; Figures S8C–S8G). This caused he-
patic infiltration and activation of immune cells, in particular
CD8+ T cells and NKT cells. In addition, activated lymphocytes
were also observed in the spleen, indicating a diet-induced sys-
temic immune activation or dissemination of T cells activated in
the liver. However, the exact mechanisms of immune cell activa-
tion and which antigens generated during hypercaloric nutrition
trigger CD8+ T cell and NKT cell activation will require further
investigation.
NASH patients displayed significantly increased amounts of
hepatic CD8+ T cells and NKT cells compared with non-diseased
controls. However, an increase of CD8+ T cells and/or NKT cells, October 13, 2014 ª2014 Elsevier Inc. 561
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CD8+ and NKT Cells Promote NASH and NASH-Induced HCCwas also found in patients with ASH, chronic HCV infection, and
NASH-related HCC. Taking into account that ASH and NASH are
not always clinically distinguishable and also share partially over-
lapping pathophysiologies (Cope et al., 2000; Petrasek et al.,
2013), and that steatosis (and occasionally steatohepatitis) is a
hallmark of HCV genotype 3 infection (Rubbia-Brandt et al.,
2000), it cannot be expected that the hepatic immune response
we describe is exclusively found in NASH. LIGHT expression,
however, was significantly upregulated in the livers of NASH pa-
tients, but not in the livers of patients with ASH or chronic HCV
infection. Consistently, costaining indicates that CD8+ T cells
and CD57+CD3+ cells in the liver are the major source of LIGHT.
Despite weight gain and decreased glucose tolerance, CD-
HFD Rag1/ showed a reduced liver-to-body weight ratio,
implicating lymphocytes as drivers of liver pathology. The
rescued liver phenotype in CD-HFD Rag1/ mice was not due
to a deficit in FA uptake, increased hepatic endotoxin, or a
change in the GI barrier. The gut microbiota has been reported
to exacerbate hepatic steatosis and inflammation, as well
as exacerbate chemical hepatocarcinogenesis (Henao-Mejia
et al., 2012; Yoshimoto et al., 2013). However, mixing and virtu-
ally equalizing the gut microbiota between Rag1/ versus
C57BL/6 mice via co-housing experiments did not affect liver
damage and NASH development.
Similar to the situation in obese humans with NASH, long-term
CD-HFD caused NASH and NASH-to-HCC transition. Our data
rather suggest the requirement for ‘‘multiple hits,’’ in line with
other reports (Caballero et al., 2009), comprising the presence
of reactive oxygen species, influx of activated CD8+ T cells and
NKT cells, and activation of distinct signaling cascades driving
NAFLD to NASH and subsequently to HCC.
We provide evidence that LTbR and canonical NF-kB signaling
in hepatocytes are crucial for the transition from NASH to HCC:
IkkbDhep and LtbrDhep mice displayed a reduced HCC incidence
despite having developed overt NASH, liver damage, and
elevated serum cholesterol levels (Figure S8G). IkkbDhep mice
showed high triglyceride levels, whereas LtbrDhep mice had
reduced liver triglycerides, consistent with reports that immune
cell-initiated LTbR activation on hepatocytes affects liver lipid
homeostasis (Lo et al., 2007). Thus, similar to other models of
inflammation-induced liver cancer (Haybaeck et al., 2009; Pikar-
sky et al., 2004), canonical NF-kB and LTbR signaling are critical,
hepatocyte-intrinsic modulators of NASH to HCC transition but
have distinct functions with regard to hepatic lipid uptake.
Although hepatocyte-specific deletion of NF-kB or LTbR
signaling strongly reduced HCC incidence, deletion of neither
of the two pathways sufficed to fully prevent NASH-promoted
HCC, suggesting a partial contribution of other pathways.
We detected Tp53 mutations in one-third of CD-HFD-driven
HCC, indicating that a well-known tumor suppressor gene is
altered in this model. It is conceivable that the relatively low
tumor incidence found in CD-HFD C57BL/6 mice could be
increased by feeding Tp53/ mice or other strains lacking
HCC-relevant tumors suppressor genes such as Apc or Axin1
(Zender et al., 2010).
Co-culturing primary hepatocytes with distinct immune cell
populations revealed that lymphocyte activation (as observed
in CD-HFD mice) or supernatant from activated splenocytes
strongly induces hepatocellular lipid accumulation, leading to562 Cancer Cell 26, 549–564, October 13, 2014 ª2014 Elsevier Inc.macrovesicular steatosis. Thus, immune cell/hepatocyte cross-
talk, most likely through immune cell-derived cytokines, is criti-
cally involved.
Data from CD-HFD Rag1/ mice, flow cytometry, and IHC
analyses suggested a link between particular T cell populations,
NASH, and HCC development. We reasoned that CD8+ T cells or
CD1d-restricted NKT cells might be causally linked to NASH and
subsequent HCC development. CD1d is an antigen-presenting
molecule with the capacity to bind self and foreign lipids and gly-
colipids (Godfrey et al., 2010), thus enabling metabolic immunity
via NKT cells. Indeed, b2m/ mice, which lack both CD1 and
MHCI molecules, displayed strongly reduced liver damage,
had no overt NASH, and lacked HCC, suggesting a crucial role
of CD8+ and NKT cells in NASH and HCC development.
Depletion of CD8+ T cells in CD-HFD C57BL/6 mice reversed
liver damage but left cholesterol levels unchanged, indicating
that CD8+ T cells are involved in CD-HFD-induced liver damage
rather than in modulating lipid metabolism. Moreover, LTbR
inhibition in CD-HFD C57BL/6 mice did not reduce liver dam-
age, arguing against a role of LTbR signaling in the direct
control of liver damage in this model. In line, CD-HFD LtbrDhep
mice developed liver damage and NASH. Thus, CD8+ T cells
are causally linked to liver damage in an LTbR-independent
manner.
Intriguingly, coculture of distinct lymphocyte populations with
primary hepatocytes showed that NKT cells, but neither CD8+
and CD4+ T cells nor CD19+ B cells, induce efficient FA uptake.
Thus, CD8+ T cells (with or without NKT cells) induce liver
damage in an LTbR-independent manner, whereas NKT cells
promote hepatocyte FA uptake and thereby initiate steatosis
(Figure S8E). Notably, addition of LIGHT to primary hepatocytes
sufficed to induce a strong hepatocellular lipid uptake in the
presence of FAs, whereas LTbR-Ig blocked lipid uptake by pri-
mary hepatocytes cocultivated with splenocytes from CD-HFD
mice. Thus, LIGHT signaling positively regulates hepatic lipid
uptake.
As LIGHT signaling has been implicated in the regulation of
lipid metabolism (Lo et al., 2007) and as we have observed
LIGHT and other members of the TNFSF to be upregulated on in-
trahepatic lymphocytes and splenocytes in CD-HFD C57BL/6
mice, we reasoned that CD-HFD Light/ mice might display
reduced NASH and HCC incidence. We found that altered
expression of genes involved in lipid metabolism we had
observed in CD-HFD C57BL/6 mice was restored in CD-HFD
Light/ livers. Surprisingly, LIGHT deficiency prevented liver
damage and NASH and HCC development and led to a strong
reduction in hepatic NKT cells, leaving CD8+ T cell numbers un-
affected. Thus, the rescued phenotype in Light/mice could be
either directly attributed to the lack of LIGHT or might be the
result of reduced intrahepatic NKT cells. Notably, liver damage
was prevented despite activated hepatic CD8+ T cells in Light/
mice, suggesting that CD8+ T cells alone were not sufficient to
cause liver damage in the absence of NKT cells. Therefore,
both CD8+ and NKT cells contribute to the induction of liver dam-
age in CD-HFD (Figure S8F).
Our study reveals a cross-talk of CD8+ T cells, NKT cells, and
their secreted cytokines with hepatocytes in NASH development
and the subsequent transition to HCC. Our results indicate that
NASH and HCC development is not merely the consequence
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CD8+ and NKT Cells Promote NASH and NASH-Induced HCCof chronic liver damage but is triggered by defined signaling
pathways. CD8+ T cells and NKT cells enhance steatosis,
NASH development, and transition to HCC, adding knowledge
of how the immune system contributes to NASH-driven liver
damage and HCC. Our data suggest that efficient reduction in
the numbers of hepatic CD8+ and/or NKT cells or prevention of
their cross-talk with hepatocytes by targeting particular signaling
pathways has the potential to minimize the risk for developing
liver damage, dietary-induced NASH, and HCC.
EXPERIMENTAL PROCEDURES
Human Material
Formalin-fixed, paraffin-embedded normal or tumor tissue was retrieved from
the archives and biobank of the Institute of Surgical Pathology, University Hos-
pital Zurich, for IHC and molecular analysis. This study was approved by the
local ethics committee of the Canton of Zurich (Kantonale Ethikkommission
[KEK] Zurich: KEK-StV 26-2005 and KEK-ZH-Nr. 2013-0382). In line with the
regulation of KEK, individual informed consent from all patients was not
required for this kind of retrospective analysis on patients’ material.
Mice
Animals were maintained under specific pathogen-free conditions, and exper-
iments were conducted in accordance with the guidelines of the Swiss Animal
Protection Law and were approved by the Veterinary Office of the Canton of
Zurich (licenses 63/2011 and 136/2014). C57BL/6J mice were purchased
from Harlan or obtained from own breedings. IkkbDhep mice (Maeda et al.,
2005), Ccr2/ mice (Kuziel et al., 1997), Light/ mice (Scheu et al., 2002),
and LtbrDhep mice (generated by crossing of LtbrloxP/loxP [Wang et al., 2010]
with Alb-Cre mice [Haybaeck et al., 2009]) were bred in house, and Rag1/
and b2m/ mice were purchased from Jackson Laboratories and bred in
house. Four- to 5-week-old mice were fed with ND (Provimi Kliba), HFD
(Research Diets; D12451), or CD-HFD (Research Diets; D05010402). For
co-housing experiments, mice were housed in the same cage after weaning.
In Vitro FA Uptake
Primary hepatocytes were isolated and in dishes with or without splenocytes
(5:1 ratio unless otherwise indicated) isolated from 6-month-old ND or CD-
HFD C57BL/6 mice for 2 hr in Williams E medium. FAs (alkyne-oleate
[66 mM] and alkyne-palmitate [33 mM]) were added for 10 min. After washing,
lipids were extracted in chloroform-methanol.
Flow Cytometry
Livers were minced and hepatic lymphocytes were purified using a Ficoll
gradient. A FACSCanto II or Fortessa (BD Biosciences) and FlowJo sofware
(TreeStar) were used for acquisition and data analysis.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism software version 5.0
(GraphPad Software) or SPSS (SPSS, Inc.). All data were analyzed by analysis
of variance with the post hoc Bonferroni multiple comparison test. Analysis
of two samples was performed with Student’s t test, and statistics for HCC
incidence were calculated using Fisher’s exact test. Statistical significance
is indicated as follows: ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p <
0.05; ‘‘n.s.’’ indicates not significant.
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